The direct-to-consumer health-care startup Ro launched a new free tool to help patients determine whether their insurance will cover a class of weight loss and diabetes medications called GLP-1s.Ro said it hopes its new tool will be able to help patients understand their coverage options so they can decide how to pursue weight loss, and it could also drive some patients to join the company's GLP-1 program.
Patients in Ro's program can get prescribed a GLP-1, and the company also offers compounded versions of the medication when the branded versions are in short supply. Compounded GLP-1s are custom-made alternatives to brand drugs designed to meet a specific patient's needs. After around one to three days, patients will receive a personalized report that shows whether they have coverage, whether a prior authorization is required and what their estimated copay will be for each major GLP-1 medication. All of the information in the report comes directly from insurers.
One sample report involving a patient, provided by Ro, showed a summary of the insurance coverage, supply availability and estimated copay for each drug, including Wegovy, Ozempic,For example, the report said the patient has insurance coverage for Wegovy and meets the eligibility requirements for their plan's prior authorization, such as having a certain body mass index and other health conditions like diabetes and heart disease.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: nbcsandiego - 🏆 524. / 51 続きを読む »